Alzheimer's diagnostic guideline validation [electronic resource] : exploration of next steps : workshop summary /
Diana E. Pankevich, Theresa Wizemann, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
Washington, D.C. : National Academies Press, c2012.
1 online resource (PDF file (various pagings)) : ill.
030922554X, 0309225558 (electronic bk.), 1280380233, 9780309225540, 9780309225557 (electronic bk.), 9781280380235
More Details
Washington, D.C. : National Academies Press, c2012.
0309225558 (electronic bk.)
9780309225557 (electronic bk.)
standard identifier
Licensed for access by TSH users only.
contents note
Background -- Comparing the guidelines -- Validating the new diagnostic guidelines: lessons learned from cardiovascular disease and cholesterol -- Moving forward: validation of the new diagnostic guidelines.
At the request of the Alzheimer's Association, the Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders planned and hosted a 2-hour public workshop at the 2011 Alzheimer's Association International Conference (AAIC). Held in Paris, France, on July 18, 2011, the session brought together key stakeholders to discuss next steps in the validation of the new diagnostic guidelines for Alzheimer's disease (AD), specifically, the revised guidelines recently proposed in papers by the International Working Group for New Research Criteria for the Diagnosis of Alzheimer's Disease, and three working groups under the auspices of the National Institute on Aging (NIA) and the Alzheimer's Association.
catalogue key
Includes bibliographical references.
This project was supported by contracts between the National Academy of Sciences and the Alzheimer's Association; AstraZeneca Pharmaceuticals, Inc.; CeNeRx Biopharma; the Department of Health and Human Services' National Institutes of Health (NIH, Contract No. N01-OD-4-2139) through the National Institute of Mental Health, National Institute of Neurological Disorders and Stroke; National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and National Eye Institute, NIH Blueprint for Neuroscience Research, Eli Lilly and Company; GE Healthcare, Inc.; GlaxoSmithKline, Inc.; Johnson & Johnson Pharmaceutical Research and Development, LLC; Merck Research Laboratories; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. OIA-0753701); the Society for Neuroscience; and Wyeth Research, Inc.

  link to old catalogue

Report a problem